Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
93 stopped studies mapped to Malignant Mesothelioma and descendants · 88% state a reason
Over the 93 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00003508 | Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Withdrawn due to slow enrollment | Enrollment / accrual |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | Phase 1 | withdrawn | Dec 17, 2019 | Raphael Bueno, MD | Funding complications coupled with competing scientific objectives | Funding |
| NCT02672033 | Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating… | N/A | terminated | Feb 3, 2016 | Jonsson Comprehensive Cancer Center | slow enrollment | Enrollment / accrual |
| NCT02357147 | Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and…(ARTEMIS) | Phase 2 | terminated | Feb 6, 2015 | Morphotek | Due to business reasons | Sponsor / business decision |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and… | Phase 1 | terminated | Jun 14, 2010 | National Cancer Institute (NCI) | Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same… | Enrollment / accrual |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | Phase 2 | terminated | Jun 20, 2012 | National Cancer Institute (NCI) | Study closed due to low accrual. | Enrollment / accrual |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | Early Phase 1 | terminated | Aug 10, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03436732 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With… | Phase 1 | terminated | Feb 19, 2018 | National Cancer Institute (NCI) | Due to fatal occurrence (pneumonitis) attributed to one of the study drugs. | Other (stated, no rule matched) |
| NCT01583686 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 24, 2012 | National Cancer Institute (NCI) | Study terminated due to slow/insufficient accrual. | Enrollment / accrual |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT03175172 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural… | Phase 2 | terminated | Jun 5, 2017 | Aduro Biotech, Inc. | Study was stopped due to low enrollment and lack of clinical activity. | Enrollment / accrual |
| NCT02106559 | Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy | N/A | withdrawn | Apr 8, 2014 | Ohio State University Comprehensive Cancer Center | not stated | Not stated |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | Phase 2 / Phase 3 | terminated | Jul 24, 2013 | Boehringer Ingelheim | not stated | Not stated |
| NCT00898547 | Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant… | — | terminated | May 12, 2009 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT01445392 | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | Phase 1 | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01325753 | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or… | N/A | withdrawn | Mar 30, 2011 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT02661659 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With… | Phase 1 | withdrawn | Jan 22, 2016 | University of Chicago | PI stopped study due to inability to accrue. | Enrollment / accrual |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | Phase 1 / Phase 2 | suspended | Jun 26, 2012 | Oshadi Drug Administration | not stated | Not stated |
| NCT01188486 | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | N/A | terminated | Aug 25, 2010 | Stanford University | Business decision | Sponsor / business decision |
| NCT01604005 | PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma(PIT) | Phase 3 | terminated | May 23, 2012 | Brynn Chappell | CI Decision:That once the last patient has reached 1 year follow-up, no further follow up needs to… | Enrollment / accrual |
| NCT00895648 | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for… | Phase 2 | terminated | May 8, 2009 | University Health Network, Toronto | low accrual due to competing study for same group of patients | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT00604461 | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With… | Phase 1 / Phase 2 | terminated | Jan 30, 2008 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | Phase 2 | terminated | Jun 6, 2013 | Verastem, Inc. | Interim analysis-DSMB stated good safety profile but lack of efficacy | Safety / toxicity |
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in… | Phase 1 | terminated | Feb 26, 2015 | Verastem, Inc. | not stated | Not stated |
| NCT02639767 | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for… | Phase 1 | withdrawn | Dec 24, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT01861301 | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | Phase 2 | terminated | May 23, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00597116 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant… | Phase 2 | terminated | Jan 17, 2008 | Genzyme, a Sanofi Company | Recruitment stopped according to early stopping rule (by protocol) | Enrollment / accrual |
| NCT01770665 | Validation of the MiCK Assay(MiCK Assay) | — | terminated | Jan 18, 2013 | Pierian Biosciences | Assay being revised and re-validated. | Other (stated, no rule matched) |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated… | Phase 2 | terminated | Sep 14, 2005 | Dana-Farber Cancer Institute | lack of acurral | Other (stated, no rule matched) |
| NCT02511600 | Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing… | Phase 3 | withdrawn | Jul 30, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00733252 | Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease | — | withdrawn | Aug 13, 2008 | Case Comprehensive Cancer Center | Low interest | Other (stated, no rule matched) |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma…(DOVE-M) | Phase 2 | terminated | Jan 16, 2013 | Ontario Clinical Oncology Group (OCOG) | Stage 1 accrual completed. Study did not proceed to Stage 2 accrual. | Enrollment / accrual |
| NCT00748085 | CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect…(ICEtheMAD) | N/A | terminated | Sep 8, 2008 | CSA Medical, Inc. | Business Reasons | Sponsor / business decision |
| NCT00785239 | CryoSpray Ablation(tm)Thoracic Patient Registry | — | withdrawn | Nov 5, 2008 | CSA Medical, Inc. | Business Reasons | Sponsor / business decision |
| NCT00027508 | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma | Phase 2 | terminated | Jan 15, 2004 | PharmaMar | Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained. | Enrollment / accrual |
| NCT00668499 | A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2008 | University of Southern California | Sponsor withdrew support | Other (stated, no rule matched) |
| NCT01105390 | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural… | Phase 2 | withdrawn | Apr 16, 2010 | National Cancer Institute (NCI) | withdrawn | Other (stated, no rule matched) |
| NCT00028782 | EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing… | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01353482 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With…(MESO-02) | Phase 1 / Phase 2 | withdrawn | May 13, 2011 | University College, London | UCL CTC were informed by Merck Sharp \& Dohme on 22.08.11 that support for the trial had been… | Other (stated, no rule matched) |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced… | Phase 1 | terminated | Jan 3, 2008 | Anza Therapeutics, Inc. | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 27, 2021source: clinicaltrials